Home > Journals > International Angiology > Past Issues > International Angiology 2016 August;35(4) > International Angiology 2016 August;35(4):365-8

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Cite this article as

 

REVIEWS   

International Angiology 2016 August;35(4):365-8

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Novel oral anticoagulants in the treatment of cerebral venous thrombosis

Gergely FEHER 1, Zsolt ILLES 2, Samuel KOMOLY 3, David HARGROVES 4

1 Szigetvar Hospital, Szigetvár, Hungary; 2 University of Southern Denmark, Odense, Denmark; 3 University of Pecs, Pécs, Hungary; 4 William Harvey Hospital, Kent, UK


PDF


Cerebral venous thrombosis (CVT) is an uncommon cause of stroke with extremely diverse clinical features, predisposing factors, brain imaging findings, and outcome. Anticoagulation is the cornerstone of CVT management, however, it is not supported by high-quality evicence. Novel oral anticoagulants (NOACs) have been extensively studied in patients with deep vein thrombosis, pulmonary embolism and non-valvular atrial fibrillation. The aim of our work was to review the available evidence for NOACs in the treatment of CVT. Based on our literature search there is insufficient evidence to support the use of NOACs in CVT, although case series with rivaroxaban and dabigatran have showed promising results.

top of page